CD28 / DyLight 488 / YTH913.12
Product Details
| Description | NB100-64867 recognizes the human CD28 cell surface antigen, a 44kD glycoprotein expressed by a subset of T lymphocytes. The antibody enhances the MLR response. It has been reported that this clone also recognizes an epitope of CD28 expressed by NK cells, which is not recognized by clones of 9.3 or CD28.2.(2) | |
|---|---|---|
| Conjugate | DyLight 488 | |
| Clone | YTH913.12 | |
| Target Species | Human | |
| Applications | FC, IHC-Fr, IHC | |
| Supplier | Novus Biologicals | |
| Catalog # | Sign in to view product details, citations, and spectra | |
| Size | ||
| Price | ||
| Antigen | ||
| Host | ||
| Isotype |
About CD28
The protein encoded by this gene is essential for T-cell proliferation and survival, cytokine production, and T-helper type-2 development. Several alternatively spliced transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Jul 2011]
The protein encoded by this gene is essential for T-cell proliferation and survival, cytokine production, and T-helper type-2 development. Several alternatively spliced transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Jul 2011]
About DyLight 488
DyLight™ 488 has an excitation peak at 493 nm and an emission peak at 518 nm and is spectrally similar to Alexa Fluor™ 488, fluorescein and FITC. DyLight™ 488 is most commonly used in flow cytometery, and fluorescence microscopy applications.
DyLight™ 488 has an excitation peak at 493 nm and an emission peak at 518 nm and is spectrally similar to Alexa Fluor™ 488, fluorescein and FITC. DyLight™ 488 is most commonly used in flow cytometery, and fluorescence microscopy applications.
Experiment Design Tools
Panel Builders
Looking to design a Microscopy or Flow Cytometry experiment?
Validation References
| Additional Sources |
|
|---|
Reviews & Ratings
| Reviews |
|---|
Looking for more options?
2300 CD28 antibodies from over 48 suppliers available with over 139 conjugates.
